Omeros Corporation

NasdaqGM:OMER Stock Report

Market Cap: US$597.5m

Omeros Balance Sheet Health

Financial Health criteria checks 0/6

Omeros has a total shareholder equity of $-154.2M and total debt of $413.4M, which brings its debt-to-equity ratio to -268.2%. Its total assets and total liabilities are $313.3M and $467.5M respectively.

Key information

-268.2%

Debt to equity ratio

US$413.43m

Debt

Interest coverage ration/a
CashUS$123.16m
Equity-US$154.17m
Total liabilitiesUS$467.51m
Total assetsUS$313.34m

Recent financial health updates

Recent updates

Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns

Nov 17

Omeros: Troubled Company Working Its Way Out Of The Morass

Jul 19

Omeros: Still Worth A Look Despite Narsoplimab Woes

Feb 14

Is Omeros (NASDAQ:OMER) A Risky Investment?

Jul 26
Is Omeros (NASDAQ:OMER) A Risky Investment?

Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt

Mar 17
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt

Omeros: Taking It To The Max

Oct 05

Omeros falls 11% after reporting clinical data for COVID-19 therapy

Sep 15

Omeros: Managing An Investment After A Winning Trade

Aug 16

Omeros granted FDA’s Orphan Drug designation for PNH candidate

Jul 28

Omeros: Follow The Bouncing Ball

Jul 04

Omeros: On Death's Door

Jun 02

Omeros: The Weight Of The Wait, A Conundrum

May 03

Omeros: Despite Its Promise, The CRL Is A Huge Obstacle

Feb 21

Omeros: A New Year Beckons

Dec 06

Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates

Dec 04
Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates

Omeros: What's Left

Oct 15

Omeros: The Prize Is Nigh (Again)

Sep 14

Omeros: PDUFA Delay Presents An Opportunity

Jul 03

Omeros posts preliminary results from early-stage OMS906 trial

Jun 09

Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?

Jun 05
Should Shareholders Reconsider Omeros Corporation's (NASDAQ:OMER) CEO Compensation Package?

Omeros posts preliminary results from COVID-19 patients treated with narsoplimab

May 28

Financial Position Analysis

Short Term Liabilities: OMER has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: OMER has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: OMER has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: OMER's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OMER has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OMER has less than a year of cash runway if free cash flow continues to grow at historical rates of 9.8% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:34
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Omeros Corporation is covered by 20 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gregory HarrisonBofA Global Research
Jason KolbertB. Riley Wealth
Ritu BaralCanaccord Genuity